Browse the evidence

Obesity increases the risk of kidney stones (nephrolithiasis) and kidney cancer through mechanisms involving insulin resistance, acidic urine, and adipose-derived inflammatory factors.

If you are overweight, you are at higher risk for kidney stones and kidney cancer. This is partly due to how your body processes acids and minerals. Staying well-hydrated and maintaining a healthy weight through balanced eating can help reduce these risks. Be cautious with extreme weight loss methods, as they can sometimes increase stone risk.

Resistance exercise-induced skeletal muscle hypertrophy is primarily regulated by internal biological variables (e.g., mechanotransduction, mTORC1 signaling, ribosomal biogenesis) rather than external programming alone, with internal variables acting as the dominant determinant of the hypertrophic response.

To maximize muscle growth, focus on consistent resistance training that provides mechanical load. Your body's internal biological machinery (signaling pathways, gene expression) will determine how much muscle you build from that load. Don't chase acute hormone spikes or muscle soreness, as these are not the primary drivers of long-term hypertrophy.

Two weeks of acute physical inactivity (step count <1,000/day) causes a significant decline in glycemic control and integrated muscle protein synthesis in overweight, prediabetic older adults, and these metabolic impairments fail to recover after two weeks of returning to habitual activity levels.

If you are an older adult with prediabetes, even a short period of reduced activity (fewer than 1,000 steps a day) can worsen your blood sugar control and muscle building processes. Crucially, simply going back to your normal activity level for two weeks may not be enough to fix these issues. You may need to be more proactive, such as engaging in specific exercise or medical management, to prevent these declines and help your body recover faster after periods of inactivity.

Maintenance of weight loss is physiologically distinct from active weight loss, characterized by a 'perfect physiological storm' of increased appetite and decreased energy expenditure that actively opposes weight maintenance.

Accept that maintaining weight loss is biologically harder than losing it. Your body will fight back with increased hunger and lower energy expenditure. To succeed, you must implement strategies that account for this 'storm,' such as higher physical activity levels to offset the metabolic slowdown, rather than relying solely on willpower or extreme restriction.

Leptin repletion to pre-weight-loss levels reverses most physiological adaptations (hypometabolism and hyperphagia) in weight-reduced individuals, proving that low leptin drives these adaptations.

While leptin therapy is not currently a standard commercial treatment for obesity, this research highlights that the biological drive to regain weight is mediated by low leptin levels. This underscores why weight maintenance is so difficult and why future pharmacotherapies targeting these pathways (like GLP-1 agonists which mimic satiety signals) are crucial.

An isocaloric ketogenic diet decreases insulin-mediated antilipolysis (the ability of insulin to suppress fat breakdown) compared to a baseline diet, regardless of the meal consumed.

On a ketogenic diet, your body's fat cells become less responsive to insulin's signal to stop breaking down fat. This means insulin is less effective at suppressing fat release, even if your blood sugar control remains stable. This is a key metabolic shift to understand when managing body composition on keto.

AOM therapy requires monitoring and potential dose reduction of concomitant medications for diabetes and hypertension due to rapid weight loss and improved metabolic parameters.

If you take medication for diabetes or high blood pressure, tell your doctor you are starting an AOM. Your doses may need to be lowered quickly as you lose weight to prevent dangerous drops in blood sugar or blood pressure.

Higher resistance training volume (3 sets vs 1 set) yields greater muscle hypertrophy and strength gains, but this benefit is contingent upon the individual's capacity for ribosome biogenesis (total RNA accumulation).

If you are new to resistance training, doing 3 sets per exercise will likely yield better muscle and strength gains than doing just 1 set. However, your body's ability to produce ribosomes (total RNA) determines how much benefit you get from those extra sets. If you are short on time, 1 set is still effective, but 3 sets is superior for maximizing growth.

Metformin is the primary first-line oral treatment for type 2 diabetes across all age groups due to its efficacy, versatility, and cost-effectiveness, with benefits extending to cardiovascular and potential anti-neoplastic properties.

Start with metformin as your primary medication. It is the standard, effective, and affordable choice for managing blood sugar. While it may cause mild stomach issues initially, it is generally well-tolerated and helps protect your heart and kidneys over the long term.

GLP-1 receptor agonists improve cardiovascular risk factors (blood pressure, lipid profiles, endothelial function) and reduce cardiovascular events in patients with type 2 diabetes and obesity.

GLP-1 injections not only help with weight and blood sugar but also improve heart health by lowering blood pressure, improving cholesterol, and reducing inflammation. They are recommended for patients with T2DM and obesity to reduce cardiovascular risk.

Statins are safe and effective as first-line treatment for hyperlipidemia in MASLD patients, despite under-prescription, and may reduce cardiovascular events and liver disease burden.

If you have MASLD and high cholesterol or CVD risk, ask your doctor about statins. They are safe for your liver, even if you have some liver scarring, and are the first-line treatment to lower your risk of heart disease. Do not avoid them due to fear of liver damage.

Tirzepatide treatment significantly reduces the 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) in adults with obesity or overweight without diabetes compared to placebo.

If you have obesity or overweight without diabetes, treatment with tirzepatide (a once-weekly injection) combined with lifestyle changes can significantly lower your calculated 10-year risk of heart disease compared to placebo. This benefit was observed across different baseline risk levels, suggesting it may be a valuable option for long-term cardiovascular health improvement in this population.

Certain diabetes medications (GLP-1 agonists and SGLT2 inhibitors) promote weight loss, whereas others (insulin, sulphonylureas, thiazolidinediones) cause weight gain, influencing the choice of therapy in obese patients.

When choosing diabetes medication, ask your doctor about its effect on your weight. Some drugs (like GLP-1 agonists and SGLT2 inhibitors) help you lose weight, while others (like insulin and sulphonylureas) may cause weight gain. If you have obesity, your doctor should prioritize medications that support weight loss.

SGLT-2 inhibitors reduce body weight (0.9-2.5 kg) and improve cardiovascular and renal outcomes in patients with diabesity by inducing glycosuria, making them a valuable class of medication for managing both metabolic and organ-specific risks.

SGLT-2 inhibitors (like Jardiance or Farxiga) are oral diabetes medications that also help with modest weight loss (1-2.5 kg) and protect your heart and kidneys. They work by removing excess sugar through urine. While this can increase the risk of yeast infections or UTIs, good hygiene and doctor guidance can manage this. They are particularly beneficial if you have heart or kidney risks associated with your diabetes.

Higher dietary glycemic load (GL) is associated with a significantly increased risk of coronary heart disease (CHD), with a relative risk of 1.44 per 65 g/d increase in GL among populations using valid dietary instruments.

To lower your risk of heart disease, pay attention to the glycemic load of your diet. This means choosing carbohydrates that have less impact on your blood sugar. The study suggests that for every 65 grams of glycemic load you consume daily, your risk of coronary heart disease increases by about 44% compared to lower intake, assuming you use accurate dietary tracking. Prioritize low-GL foods like vegetables, legumes, and whole grains over high-GL refined carbs.

Higher dietary glycemic index (GI) is associated with an increased risk of coronary heart disease, with a relative risk of 1.24 per 10 unit increase in GI on the glucose scale.

Choose carbohydrates with a lower Glycemic Index (GI) to support heart health. The study indicates that for every 10-unit increase in GI, your risk of coronary heart disease increases by about 24%. This means prioritizing foods that digest slowly and cause a smaller spike in blood sugar, such as legumes, whole grains, and non-starchy vegetables, over refined grains and sugary foods.

The risk of coronary heart disease from carbohydrate intake is significantly dependent on the Glycemic Index (GI) of the carbohydrates consumed, with higher GI amplifying the risk.

When consuming carbohydrates, their quality (Glycemic Index) significantly impacts your heart disease risk. The study shows that for every 98 grams of carbohydrates consumed, the risk of CHD increases by 66% for every 10-unit increase in the GI of those carbs. To protect your heart, choose carbohydrates with a lower GI, such as whole grains, legumes, and vegetables, and limit high-GI refined carbohydrates.

Intensive lifestyle intervention (ILI) aimed at weight loss reduces the incidence of obesity-related cancers by 16% in adults with type 2 diabetes, although the result was not statistically significant due to insufficient statistical power.

For individuals with type 2 diabetes and obesity, engaging in a structured weight loss program involving calorie restriction (1,200-1,800 kcal/day), moderate exercise (175 mins/week), and behavioral counseling can significantly lower the risk of developing obesity-related cancers. While the statistical evidence in this specific trial was borderline due to sample size, the consistent trend toward reduced risk suggests that maintaining a healthy weight is a critical cancer prevention strategy for this population.

GLP-1-based therapies achieve clinically meaningful weight loss (exceeding 10%) in type 2 diabetes and obesity by leveraging the gut-brain axis, specifically through the activation of satiety circuits in the brainstem (area postrema and nucleus of the solitary tract).

GLP-1 medications are currently the most effective pharmacological option for significant weight loss in people with obesity or type 2 diabetes. They work by mimicking a gut hormone that signals fullness to the brain. While they are injections, they are usually taken once a week. Common side effects like nausea are often temporary and can be managed by adjusting the dose. Consult a doctor to see if this treatment is appropriate for your specific health profile.

12 weeks of 500 mg/day Sensoril supplementation favors body mass distribution by reducing the increase in the android/gynoid ratio compared to placebo, without significantly altering total body fat or lean mass.

If you are looking to optimize body composition, 500 mg/day of Sensoril may help you maintain a healthier fat distribution (lower android/gynoid ratio) compared to placebo, even if it doesn't directly cause fat loss or muscle gain. This is a subtle benefit that supports long-term metabolic health.

High glycemic index (GI) carbohydrates induce metabolic damage primarily through rapid glucose absorption in the proximal small intestine, which stimulates GIP release from K cells, leading to lipogenesis, fatty liver, insulin resistance, and inflammation, whereas low GI carbohydrates bypass this mechanism.

To minimize metabolic damage from carbohydrates, prioritize foods with a low glycemic index (like isomaltulose, legumes, or whole grains) over high GI foods (like sucrose or white bread). This is because high GI foods are rapidly absorbed in the upper intestine, triggering GIP release which promotes fat storage, liver fat, and inflammation. Low GI foods are absorbed more slowly, bypassing the GIP-triggering K cells and instead stimulating beneficial GLP-1 release.

The hypertrophic benefit of creatine supplementation is modestly greater in younger adults compared to older adults, although the effect remains small in both groups.

Younger lifters may see a slightly better muscle growth boost from creatine than older lifters, but the difference is small. Older adults should still use creatine as it provides a small benefit, even if the magnitude is lower than in youth.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) provide a net health benefit for weight loss in non-diabetic adults with obesity, but only when the treatment goal is achieving ≥10% body weight loss; achieving 5% weight loss results in a net harm due to side effects.

If you are considering GLP-1 medications for weight loss without diabetes, understand that these drugs are most effective and 'worth it' if you aim to lose 10% or more of your body weight. Losing only 5% may actually result in a net negative health outcome due to side effects like nausea and vomiting. Ensure you are committed to lifestyle changes (diet and exercise) alongside the medication, and discuss your specific weight loss goals and tolerance for side effects with your doctor.

Skeletal muscle hypertrophy from resistance training is driven primarily by chronic increases in translational capacity (ribosome biogenesis) and resting protein synthesis, rather than solely by acute post-exercise spikes in protein synthesis.

Focus on consistent resistance training over time to build more ribosomes in your muscles, which increases your baseline protein synthesis. Don't obsess over the exact timing of nutrients immediately post-workout, as total daily protein and long-term training consistency drive hypertrophy more than acute spikes.